
July 21 (Reuters) - Alkermes Plc ALKS.O:
ALKERMES ANNOUNCES POSITIVE TOPLINE RESULTS FROM VIBRANCE-1 PHASE 2 STUDY OF ONCE-DAILY ALIXOREXTON IN PATIENTS WITH NARCOLEPSY TYPE 1
ALKERMES PLC - ALIXOREXTON SHOWS SIGNIFICANT IMPROVEMENTS IN WAKEFULNESS IN NT1
ALKERMES PLC - ALIXOREXTON GENERALLY WELL TOLERATED AT ALL DOSES
ALKERMES PLC - ALIXOREXTON ADVANCING TO PHASE 3 DEVELOPMENT IN NARCOLEPSY